Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.

Abstract excerpt

The burden of HIV and HCV coinfection is estimated to affect 5-7 million people worldwide, with approximately 15-30% of people with HIV coinfected with HCV. The first oral direct-acting antivirals have shown to improve the response in patients with HIV/HCV coinfection, and more recently, other direct-acting antivirals that target various stages of the HCV life cycle have been developed, among them daclatasvir....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carbamates
• Share to Coinfection
• Share to Drug Interactions